NCT00756509 2026-01-20
Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib
Novartis
Phase 4 Completed
Novartis
Guerbet
University of Kansas Medical Center
Blueprint Medicines Corporation
Novartis
Pfizer
University of California, San Francisco
Pfizer